## UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 3, 2009

## ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

## Cytokinetics, Incorporated

File No. 000- 50633 - CF#23320

Cytokinetics, Incorporated submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-K filed on March 12, 2009.

Based on representations by Cytokinetics, Incorporated that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibits will not be released to the public for the time periods specified:

Exhibit 10.55	through April 29, 2015
Exhibit 10.62	through December 31, 2015
Exhibit 10.63	through December 31, 2015
Exhibit 10.65	through December 31, 2015
Exhibit 10.67	through December 31, 2015

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Pamela Howell Special Counsel